NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board

ZURICH and NESS ZIONA, Israel, Jan. 5, 2026 /PRNewswire/ -- NewcelX Ltd. (NASDAQ: NCEL) ("NewcelX"), a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Dr. Julien Boisdron, MD, a seasoned diabetes expert with extensive experience in Swiss big pharma leadership to its Scientific Advisory Board ("SAB"). Continue Reading Dr. Julien Boisdron, Scientific Advisory Board NewCelX: "I am honored to join NewCelX a ...